SG10201400339VA - Compositions And Methods For Topical Application And Transdermal Delivery Of Botulinum Toxins - Google Patents

Compositions And Methods For Topical Application And Transdermal Delivery Of Botulinum Toxins

Info

Publication number
SG10201400339VA
SG10201400339VA SG10201400339VA SG10201400339VA SG10201400339VA SG 10201400339V A SG10201400339V A SG 10201400339VA SG 10201400339V A SG10201400339V A SG 10201400339VA SG 10201400339V A SG10201400339V A SG 10201400339VA SG 10201400339V A SG10201400339V A SG 10201400339VA
Authority
SG
Singapore
Prior art keywords
compositions
methods
topical application
transdermal delivery
botulinum toxins
Prior art date
Application number
SG10201400339VA
Original Assignee
Revance Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US55001504P priority Critical
Application filed by Revance Therapeutics Inc filed Critical Revance Therapeutics Inc
Publication of SG10201400339VA publication Critical patent/SG10201400339VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/468The waterborne disease being caused by a bacteria
    • Y02A50/469The waterborne disease being caused by a bacteria the bacteria being clostridium botulinum, i.e. Botulism
SG10201400339VA 2004-03-03 2005-03-03 Compositions And Methods For Topical Application And Transdermal Delivery Of Botulinum Toxins SG10201400339VA (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US55001504P true 2004-03-03 2004-03-03

Publications (1)

Publication Number Publication Date
SG10201400339VA true SG10201400339VA (en) 2014-05-29

Family

ID=34919562

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201803560WA SG10201803560WA (en) 2004-03-03 2005-03-03 Compositions And Methods For Topical Application And Transdermal Delivery Of Botulinum Toxins
SG200901491-1A SG150568A1 (en) 2004-03-03 2005-03-03 Compositions and methods for topical application and transdermal delivery of botulinum toxins
SG10201400339VA SG10201400339VA (en) 2004-03-03 2005-03-03 Compositions And Methods For Topical Application And Transdermal Delivery Of Botulinum Toxins

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG10201803560WA SG10201803560WA (en) 2004-03-03 2005-03-03 Compositions And Methods For Topical Application And Transdermal Delivery Of Botulinum Toxins
SG200901491-1A SG150568A1 (en) 2004-03-03 2005-03-03 Compositions and methods for topical application and transdermal delivery of botulinum toxins

Country Status (24)

Country Link
US (2) US8398997B2 (en)
EP (3) EP2656859B1 (en)
JP (1) JP5095388B2 (en)
KR (2) KR101330775B1 (en)
CN (2) CN102357062B (en)
AU (1) AU2005218665A1 (en)
BR (1) BRPI0508410B1 (en)
CA (1) CA2558408C (en)
CR (1) CR8602A (en)
DK (3) DK2985039T3 (en)
ES (3) ES2431610T3 (en)
HK (4) HK1105774A1 (en)
HU (1) HUE025656T2 (en)
IL (4) IL177816A (en)
LT (1) LT2985039T (en)
MX (2) MXPA06009898A (en)
NO (1) NO20064490L (en)
NZ (1) NZ592041A (en)
PL (1) PL2985039T3 (en)
PT (2) PT1729821E (en)
SG (3) SG10201803560WA (en)
SI (3) SI2656859T1 (en)
TR (1) TR201815364T4 (en)
WO (1) WO2005084410A2 (en)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
US20060216313A1 (en) * 1999-08-10 2006-09-28 Allergan, Inc. Methods for treating a stricture with a botulinum toxin
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US7807780B2 (en) * 2000-07-21 2010-10-05 Revance Therapeutics, Inc. Multi-component biological transport systems
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
EP1534235B1 (en) 2002-06-25 2016-07-27 Acrux DDS Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
US7824693B2 (en) 2002-08-19 2010-11-02 Ira Sanders Treatment of fine wrinkles with clostridia neurotoxins
US20120114697A1 (en) 2002-08-19 2012-05-10 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
BR0314916A (en) 2002-10-25 2005-08-16 Foamix Ltd pharmaceutical and cosmetic foam
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
IL152486D0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US7700076B2 (en) * 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8871224B2 (en) * 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
MXPA06009897A (en) * 2004-03-03 2008-02-07 Revance Therapeutics Inc Compositions and methods for topical diagnostic and therapeutic transport.
WO2005084410A2 (en) 2004-03-03 2005-09-15 Essentia Biosystems, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US9211248B2 (en) * 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US20050220821A1 (en) * 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
US20080220021A1 (en) * 2005-02-14 2008-09-11 Pankaj Modi Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis
US9314416B2 (en) * 2005-03-03 2016-04-19 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
AU2013201374B2 (en) * 2013-03-06 2015-05-21 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
WO2007119099A2 (en) * 2005-09-12 2007-10-25 Foamix Ltd. Apparatus and method for releasing a measure of content from a plurality of containers
MX2007014101A (en) 2005-05-09 2009-02-13 Foamix Ltd Foamable vehicle and pharmaceutical compositions thereof.
KR20130114229A (en) 2005-06-03 2013-10-16 애크럭스 디디에스 피티와이 리미티드 Method and composition for transdermal drug delivery
CN101384247B (en) * 2005-07-18 2013-05-22 麻萨诸塞州洛厄尔大学 Compositions and methods for making and using nanoemulsions
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US8518414B2 (en) * 2005-11-17 2013-08-27 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
ES2648979T3 (en) 2005-12-01 2018-01-09 University Of Massachusetts Lowell Botulinum nanoemulsions
JP2009532017A (en) * 2006-02-10 2009-09-10 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア It can be introduced delivery of siRNA by the dsRNA-binding domain fusion to the PTD / CPPS
CN101074935B (en) * 2006-05-19 2011-03-23 清华大学;同方威视技术股份有限公司 Detector array and its apparatus
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
BRPI0719732A2 (en) 2006-12-01 2017-05-16 Anterios Inc peptide nanoparticles and uses thereof
CA2671447A1 (en) 2006-12-01 2008-06-12 Anterios, Inc. Amphiphilic entity nanoparticles
US20100021502A1 (en) * 2006-12-28 2010-01-28 Waugh Jacob M Compositions and Methods of Topical Application and Transdermal Delivery of Botulinum Toxins Stabililzed with Polypeptide Fragments Derived from HIV-TAT
AU2007340158A1 (en) * 2006-12-29 2008-07-10 Revance Therapeutics, Inc. Transport molecules using reverse sequence HIV-TAT polypeptides
CN102988995A (en) * 2006-12-29 2013-03-27 雷文斯治疗公司 Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from HIV-TAT
WO2008141155A1 (en) * 2007-05-11 2008-11-20 The Board Of Regents Of The University Of Nebraska Compositions for protein delivery and methods of use thereof
ES2660906T3 (en) 2007-05-31 2018-03-26 Anterios, Inc. Nucleic acid nanoparticles and uses thereof
LT2178549T (en) * 2007-07-26 2017-01-25 Revance Therapeutics, Inc. Antimicrobial peptide and compositions thereof
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009056991A2 (en) * 2007-09-04 2009-05-07 Foamix Ltd. Device for delivery of a foamable composition
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
AU2009205314A1 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
NO2379104T3 (en) * 2008-12-31 2018-07-28
CN102292126B (en) * 2008-12-31 2016-10-12 雷文斯治疗公司 Compositions and methods for treating hyperpigmentation
JP6140445B2 (en) 2009-04-01 2017-05-31 ルバンス セラピュティックス インク.Revance Therapeutics,Inc. Methods and compositions for treating skin conditions associated with vascular hypersensitivity reactions
CA2760186A1 (en) 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
EP2445521A4 (en) * 2009-06-25 2015-08-26 Revance Therapeutics Inc Albumin-free botulinum toxin formulations
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
EP2482838A4 (en) * 2009-09-30 2013-04-10 Toxcure Inc Use of botulinum neurotoxin to treat substance addictions
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
MX359879B (en) 2009-10-02 2018-10-12 Foamix Pharmaceuticals Ltd Topical tetracycline compositions.
WO2011049954A2 (en) * 2009-10-21 2011-04-28 Otonomy, Inc. Compositions comprising wnt modulators or neurotoxins for the treatment of otic disorders
US20120238969A1 (en) * 2009-10-30 2012-09-20 Revance Therapeutics, Inc Device and Method for Topical Application of Therapeutics or Cosmetic Compositions
MX2012008721A (en) * 2010-02-16 2012-08-17 Pfizer (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy) methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors.
EP2542889B1 (en) 2010-03-03 2015-03-25 3M Innovative Properties Company Ligand guanidinyl functionalized polymers
US8978936B2 (en) 2010-07-12 2015-03-17 Foamix Pharmaceuticals Ltd. Apparatus and method for releasing a unit dose of content from a container
LT2661276T (en) 2011-01-07 2017-12-11 Revance Therapeutics, Inc. Topical composition comprising botulinum toxin and a dye
US8791072B2 (en) * 2011-02-28 2014-07-29 Neuro-Ophthalmix, Llc Modulating neuromuscular junction density changes in botulinum-toxin treated tissue
US9498533B2 (en) 2011-04-04 2016-11-22 Board Of Regents Of The University Of Nebraska Drug delivery compositions and methods
WO2013142755A1 (en) * 2012-03-22 2013-09-26 Revance Therapeutics, Inc. Method of treatment of wrinkles using topical chemodenervating agents
EP2885313A4 (en) 2012-08-20 2016-03-09 Univ California Polynucleotides having bioreversible groups
MX2015005417A (en) 2012-10-28 2015-11-30 Revance Therapeutics Inc Compositions and methods for safe treatment of rhinitis.
US20140242110A1 (en) * 2013-02-28 2014-08-28 Dt Scimed, Llc Dose, localization, and formulation of botulinum toxins in skin and muscle
BR112016001696A2 (en) 2013-07-30 2017-08-01 Glaxosmithkline Ip Dev Ltd topical compositions for the treatment of excessive sweating and methods of using these
KR101997474B1 (en) 2016-06-13 2019-07-09 기초과학연구원 method for controlling neurotransmitter using the cucurbit[n]uril, and use thereof
CA2978573A1 (en) 2016-09-08 2018-03-08 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
WO2019015673A1 (en) * 2017-07-21 2019-01-24 Shanghaitech University Topical compositions and uses
US20190185523A1 (en) 2017-12-20 2019-06-20 Allergan, Inc. Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4078060A (en) * 1976-05-10 1978-03-07 Richardson-Merrell Inc. Method of inducing an estrogenic response
US4434228A (en) * 1982-04-20 1984-02-28 Genex Corporation Immobilization of biological materials in condensed polyalkyleneimine polymers
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
JPS63287730A (en) * 1987-05-20 1988-11-24 Nippon Shokubai Kagaku Kogyo Co Ltd Percutaneous absorption promoter and skin external preparation containing said promoter
US5252713A (en) 1988-09-23 1993-10-12 Neorx Corporation Polymeric carriers for non-covalent drug conjugation
US5420105A (en) 1988-09-23 1995-05-30 Gustavson; Linda M. Polymeric carriers for non-covalent drug conjugation
US5744166A (en) 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5652122A (en) 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US5877278A (en) 1992-09-24 1999-03-02 Chiron Corporation Synthesis of N-substituted oligomers
US5709861A (en) 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US6986893B2 (en) 1993-12-28 2006-01-17 Allergan, Inc. Method for treating a mucus secretion
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
EP1010431B2 (en) 1993-12-28 2010-07-14 Allergan, Inc. Botulinum toxins A for treating pain associated with smooth muscle spasms
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
NO180167C (en) 1994-09-08 1997-02-26 Photocure As Photochemical method for introducing molecules into the cell cytosol
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
GB9600272D0 (en) 1996-01-06 1996-03-06 Univ Nottingham Polymers
US6444209B1 (en) 1996-10-28 2002-09-03 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
DE69818987T2 (en) 1997-05-21 2004-07-29 The Board Of Trustees Of The Leland Stanford Junior University, Stanford Composition and method for retarding transport through biological membranes
US7150881B2 (en) * 1997-06-26 2006-12-19 Mylan Technologies, Inc. Adhesive mixture for transdermal delivery of highly plasticizing drugs
US5985434A (en) * 1997-11-25 1999-11-16 Kimberly-Clark Worldwide, Inc. Absorbent foam
AU1818299A (en) 1997-12-10 1999-06-28 Washington University Anti-pathogen system and methods of use thereof
WO1999042091A2 (en) * 1998-02-19 1999-08-26 Massachusetts Institute Of Technology Use of polycations as endosomolytic agents
US6261679B1 (en) 1998-05-22 2001-07-17 Kimberly-Clark Worldwide, Inc. Fibrous absorbent material and methods of making the same
JP2002520435A (en) 1998-07-13 2002-07-09 エクスプレション・ジェネティックス・インコーポレーテッド Soluble polyester analogs of poly -l- lysine as biodegradable gene delivery carriers
US6280937B1 (en) 1998-08-14 2001-08-28 Rigel Pharmaceuticals, Inc. Shuttle vectors
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6958147B1 (en) * 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
BR9914891A (en) * 1998-10-27 2001-07-17 Mayo Foundation Processes for wound healing enhancement
US6627632B2 (en) * 1998-12-14 2003-09-30 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
US7056656B1 (en) * 1999-01-25 2006-06-06 University Of Medicine And Dentistry Of New Jersey Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA
ES2160485B1 (en) 1999-04-23 2002-05-16 Lipotec Sa Peptide inhibitors of neuronal exocytosis, and cosmetic compositions containing pharmaceutical.
DE19925739A1 (en) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Agent with a botulinum neurotoxin
US7008924B1 (en) * 1999-07-21 2006-03-07 Amgen, Inc. VGF fusion polypeptides
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
EP2269654A3 (en) 1999-08-24 2011-04-13 Cellgate Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US20030104622A1 (en) * 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
US6544548B1 (en) * 1999-09-13 2003-04-08 Keraplast Technologies, Ltd. Keratin-based powders and hydrogel for pharmaceutical applications
US6458763B1 (en) * 1999-09-17 2002-10-01 Depuy Orthopeadics Bone sialoprotein-based compositions for enhancing connective tissue repair
US6610820B1 (en) 1999-10-12 2003-08-26 University Of Lausanne Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US6844324B1 (en) * 1999-11-12 2005-01-18 Massachusetts Institute Of Technology Modular peptide mediated intracellular delivery system and uses therefore
US7070807B2 (en) * 1999-12-29 2006-07-04 Mixson A James Branched histidine copolymers and methods for using same
US20040109871A1 (en) * 2000-01-06 2004-06-10 Pascual David W. M cell directed vaccines
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20020009491A1 (en) 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
US6670322B2 (en) * 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
US20040033241A1 (en) 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6903187B1 (en) 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US7807780B2 (en) * 2000-07-21 2010-10-05 Revance Therapeutics, Inc. Multi-component biological transport systems
US20030215412A1 (en) * 2000-07-21 2003-11-20 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US7491799B2 (en) 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US20030219462A1 (en) 2000-07-21 2003-11-27 Allergan Sales, Inc Clostridial neurotoxin compositions and modified clostridial neurotoxins
US6696038B1 (en) 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
US6831059B2 (en) 2000-10-20 2004-12-14 Allergan, Inc. Compositions and methods for treating gonadotrophin related illnesses
US20020127247A1 (en) * 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
US7255865B2 (en) * 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
US20020086036A1 (en) * 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
MXPA03007358A (en) * 2001-02-16 2004-12-13 Cellgate Inc Transporters comprising spaced arginine moieties.
CA2367636C (en) * 2001-04-12 2010-05-04 Lisa Mckerracher Fusion proteins
AU2002355730B2 (en) * 2001-07-27 2007-09-13 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Botulinum toxin in the treatment or prevention of acne
WO2003015698A2 (en) * 2001-08-13 2003-02-27 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
AU2002363523A1 (en) * 2001-11-07 2003-05-19 Pharmacia Corporation Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells
US7060498B1 (en) * 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
EP1461084A2 (en) * 2001-12-11 2004-09-29 Cellgate Inc. Guanidinium transport reagents and conjugates
US20030113349A1 (en) * 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
WO2003102166A2 (en) * 2002-02-26 2003-12-11 Maxygen, Inc. Novel flavivirus antigens
US7138105B2 (en) * 2002-02-27 2006-11-21 Pharmain Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US6688311B2 (en) * 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
US20030215395A1 (en) 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
US7459164B2 (en) 2002-05-28 2008-12-02 Botulinum Toxin Research Associates, Inc. Composition for therapeutic and cosmetic botulinum toxin
WO2003101484A1 (en) * 2002-05-31 2003-12-11 Thomas Jefferson University Compositions and methods for transepithelial molecular transport
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US7071167B2 (en) * 2002-11-13 2006-07-04 L'oreal Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines
US6866856B2 (en) * 2002-12-31 2005-03-15 Avon Products, Inc. Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis
WO2004084805A2 (en) 2003-03-19 2004-10-07 The J. David Gladstone Institutes Acetylated tat polypeptides and methods of use thereof
WO2004084839A2 (en) 2003-03-24 2004-10-07 Cady Roger K Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin
US20040192754A1 (en) * 2003-03-24 2004-09-30 Shapira Nathan Andrew Methods for treating idiopathic hyperhidrosis and associated conditions
WO2005030119A2 (en) * 2003-04-11 2005-04-07 Allergan, Inc. Botulinum toxin a peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
US8871224B2 (en) * 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
WO2005084410A2 (en) 2004-03-03 2005-09-15 Essentia Biosystems, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
MXPA06009897A (en) * 2004-03-03 2008-02-07 Revance Therapeutics Inc Compositions and methods for topical diagnostic and therapeutic transport.
US7691381B2 (en) 2004-04-15 2010-04-06 Allergan, Inc. Stabilized biodegradable neurotoxin implants
US20060040882A1 (en) 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
MX2007000794A (en) 2004-07-26 2007-04-09 Merz Pharma Gmbh & Co Kgaa Therapeutic composition whit a botulinum neurotoxin.
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
US9314416B2 (en) 2005-03-03 2016-04-19 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins

Also Published As

Publication number Publication date
DK2656859T3 (en) 2016-01-11
EP1729821A4 (en) 2011-03-16
EP2985039B1 (en) 2018-08-01
HK1162952A1 (en) 2016-07-29
ES2431610T3 (en) 2013-11-27
LT2985039T (en) 2018-11-12
SI2656859T1 (en) 2016-02-29
DK2985039T3 (en) 2018-11-19
KR101330775B1 (en) 2013-11-18
WO2005084410A9 (en) 2006-03-16
AU2005218665A1 (en) 2005-09-15
TR201815364T4 (en) 2018-11-21
EP1729821B1 (en) 2013-07-17
CN1946431B (en) 2011-12-07
US8404249B2 (en) 2013-03-26
HUE025656T2 (en) 2016-04-28
PT1729821E (en) 2013-10-23
EP2656859A3 (en) 2014-02-19
EP1729821A2 (en) 2006-12-13
PL2985039T3 (en) 2019-01-31
SI1729821T1 (en) 2013-12-31
IL177816D0 (en) 2006-12-31
SG10201803560WA (en) 2018-06-28
NZ592041A (en) 2012-12-21
EP2656859A2 (en) 2013-10-30
JP5095388B2 (en) 2012-12-12
CR8602A (en) 2007-11-20
IL237388A (en) 2017-07-31
MX345724B (en) 2017-02-13
IL253007D0 (en) 2017-08-31
KR20120091198A (en) 2012-08-17
BRPI0508410A8 (en) 2017-03-14
US20050196414A1 (en) 2005-09-08
EP2656859B1 (en) 2015-10-21
ES2554821T3 (en) 2015-12-23
HK1185563A1 (en) 2016-06-03
CN1946431A (en) 2007-04-11
JP2007526340A (en) 2007-09-13
IL177816A (en) 2015-02-26
NO20064490L (en) 2006-10-03
MXPA06009898A (en) 2008-02-07
US20080107690A1 (en) 2008-05-08
HK1221650A1 (en) 2017-06-09
CN102357062A (en) 2012-02-22
EP2985039A1 (en) 2016-02-17
HK1105774A1 (en) 2012-09-28
BRPI0508410B1 (en) 2017-05-09
WO2005084410A3 (en) 2006-06-29
ES2691498T3 (en) 2018-11-27
CN102357062B (en) 2015-08-05
KR20130060360A (en) 2013-06-07
KR101322433B1 (en) 2013-10-28
IL237388D0 (en) 2015-04-30
DK1729821T3 (en) 2013-10-28
CA2558408A1 (en) 2005-09-15
SG150568A1 (en) 2009-03-30
US8398997B2 (en) 2013-03-19
IL237386D0 (en) 2015-04-30
CA2558408C (en) 2014-11-18
IL237386A (en) 2017-07-31
BRPI0508410A (en) 2007-07-24
PT2656859E (en) 2016-02-24
SI2985039T1 (en) 2018-12-31
WO2005084410A2 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
EG25839A (en) Consolidating agent emulsions and associated methods
TWI352700B (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenas
IL220480A (en) 1-benzyl-pyrimidine-2,4-dione derivatives as dipeptidyl peptidase inhibitors, preparation method thereof, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments
GB0907124D0 (en) Methods and compositions relating to the control of the rates of acid-generating compounds in acidizing operations
PT3006040T (en) Methods and compositions for treating neuropathies
EP2219600A4 (en) Topical cosmetic skin lightening compositions and methods of use thereof
SI2388007T1 (en) Topical composition for use in the treatment of rosacea-induced redness
EP2099436A4 (en) Microdevice and method for transdermal delivery and sampling of active substances
AU2007208223A8 (en) Methods and compositions for treating schizophrenia
IL177717D0 (en) Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
GB2461412B (en) Methods and compositions for reduction of side effects of therapeutic treatments
IL182805D0 (en) Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
AT541906T (en) Polishing composition and polishing method
GB2423928B (en) Methods and compositions for treating pain
HK1152863A1 (en) Pharmaceutical compositions comprising botulinum neurotoxin for use in medicine and cosmetics
HK1121420A1 (en) Compositions and methods of use of antibodies against dickkopf-1 and dickkopf-4 dickkopf-1 dickkopf-4
IL173152D0 (en) Transdermal hormone delivery system: compositions and methods
IL237388A (en) Composition comprising botulinum toxin and positively charged carrier for treating hyperhidrosis
IL185256A (en) Method and composition for treating peripheral vascular diseases
DK1781256T3 (en) Phospholipid-gel composition for pharmaceutical delivery and procedures for treating diseases
PT1973549T (en) Methods and compositions for administration of iron
ZA201004091B (en) Peptidyl nitriles and uses thereof as dipeptidyl peptidase i inhibitors
IL254184D0 (en) Compositions and methods for treating collagen-mediated diseases
WO2008089087A3 (en) Tablet-in-tablet compositions
EP1800685A4 (en) Steroidal saponin pharmaceutical composition, its preparation method and use